Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Free Cash Flow: 2018-2024

Historic Free Cash Flow for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to -$87.1 million.

  • Stoke Therapeutics' Free Cash Flow fell 40.43% to -$30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 161.83%. This contributed to the annual value of -$87.1 million for FY2024, which is 5.29% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Free Cash Flow of -$87.1 million as of FY2024, which was down 5.29% from -$82.7 million recorded in FY2023.
  • Stoke Therapeutics' 5-year Free Cash Flow high stood at -$35.8 million for FY2022, and its period low was -$87.1 million during FY2024.
  • In the last 3 years, Stoke Therapeutics' Free Cash Flow had a median value of -$82.7 million in 2023 and averaged -$68.5 million.
  • Per our database at Business Quant, Stoke Therapeutics' Free Cash Flow soared by 47.45% in 2022 and then plummeted by 130.78% in 2023.
  • Over the past 5 years, Stoke Therapeutics' Free Cash Flow (Yearly) stood at -$43.3 million in 2020, then plummeted by 57.55% to -$68.2 million in 2021, then spiked by 47.45% to -$35.8 million in 2022, then tumbled by 130.78% to -$82.7 million in 2023, then dropped by 5.29% to -$87.1 million in 2024.